Trial Outcomes & Findings for Wave Crossover ECP Study for Simplified Therapy (NCT NCT06571370)
NCT ID: NCT06571370
Last Updated: 2026-04-07
Results Overview
The primary effectiveness endpoint was the average Diastolic Augmentation (DA) ratio for the 8th minute of compressions with each ECP device tested for each participant, as identified by the blinded Independent Waveform Evaluator. Diastolic Augmentation (DA) ratio, also referred to as Diastolic/Systolic (D/S) ratio and Effectiveness Ratio (ER), noninvasively characterizes the hemodynamic effect and thus the clinical effectiveness of ECP treatment. DA ratio is a unitless measure which is "calculated as the ratio of the peak diastolic amplitude divided by the peak systolic amplitude" \[Suresh et al., 1998\]. In a typical, non-augmented, cardiac cycle, the diastolic peak is seen as a small increase in the arterial waveform just after the aortic valve closes (dicrotic notch). With augmentation, the peak diastolic amplitude is distinctly elevated and may reach a significant proportion of the peak systolic amplitude or in some cases exceed it.
COMPLETED
NA
52 participants
During treatment, measured at the 8th minute of compressions
2026-04-07
Participant Flow
60 subjects screened - 8 screen fails = 52 subjects randomized
Participant milestones
| Measure |
Pression Wave PRO ECP System, Then Predicate ECP Device
Participant receives 10 minutes of compressions first with Pression Wave PRO ECP System, then with Predicate ECP Device
|
Predicate ECP Device, Then Pression Wave PRO ECP System
Participant receives 10 minutes of compressions first with Predicate ECP Device, then with Pression Wave PRO ECP System
|
|---|---|---|
|
First ECP Round (Day 0)
STARTED
|
26
|
26
|
|
First ECP Round (Day 0)
COMPLETED
|
25
|
26
|
|
First ECP Round (Day 0)
NOT COMPLETED
|
1
|
0
|
|
Second ECP Round (Day 0)
STARTED
|
25
|
26
|
|
Second ECP Round (Day 0)
COMPLETED
|
22
|
26
|
|
Second ECP Round (Day 0)
NOT COMPLETED
|
3
|
0
|
|
Evaluable Data Determination
STARTED
|
22
|
26
|
|
Evaluable Data Determination
COMPLETED
|
21
|
26
|
|
Evaluable Data Determination
NOT COMPLETED
|
1
|
0
|
Reasons for withdrawal
| Measure |
Pression Wave PRO ECP System, Then Predicate ECP Device
Participant receives 10 minutes of compressions first with Pression Wave PRO ECP System, then with Predicate ECP Device
|
Predicate ECP Device, Then Pression Wave PRO ECP System
Participant receives 10 minutes of compressions first with Predicate ECP Device, then with Pression Wave PRO ECP System
|
|---|---|---|
|
First ECP Round (Day 0)
PPG signal could not be obtained
|
1
|
0
|
|
Second ECP Round (Day 0)
Withdrawal by Subject
|
3
|
0
|
|
Evaluable Data Determination
Data file corrupted
|
1
|
0
|
Baseline Characteristics
Wave Crossover ECP Study for Simplified Therapy
Baseline characteristics by cohort
| Measure |
Pression Wave PRO ECP System, Then Predicate ECP Device
n=25 Participants
Participant receives 10 minutes of compressions first with Pression Wave PRO ECP System, then with Predicate ECP Device
|
Predicate ECP Device, Then Pression Wave PRO ECP System
n=26 Participants
Participant receives 10 minutes of compressions first with Predicate ECP Device, then with Pression Wave PRO ECP System
|
Total
n=51 Participants
Total of all reporting groups
|
|---|---|---|---|
|
Race (NIH/OMB)
Black or African American
|
11 Participants
n=527 Participants
|
13 Participants
n=527 Participants
|
24 Participants
n=1054 Participants
|
|
Age, Continuous
|
60.9 Years
STANDARD_DEVIATION 9.2 • n=527 Participants
|
60.8 Years
STANDARD_DEVIATION 9.1 • n=527 Participants
|
60.9 Years
STANDARD_DEVIATION 9.1 • n=1054 Participants
|
|
Sex: Female, Male
Female
|
17 Participants
n=527 Participants
|
7 Participants
n=527 Participants
|
24 Participants
n=1054 Participants
|
|
Sex: Female, Male
Male
|
8 Participants
n=527 Participants
|
19 Participants
n=527 Participants
|
27 Participants
n=1054 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
1 Participants
n=527 Participants
|
0 Participants
n=527 Participants
|
1 Participants
n=1054 Participants
|
|
Race (NIH/OMB)
Asian
|
1 Participants
n=527 Participants
|
0 Participants
n=527 Participants
|
1 Participants
n=1054 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=527 Participants
|
0 Participants
n=527 Participants
|
0 Participants
n=1054 Participants
|
|
Race (NIH/OMB)
White
|
11 Participants
n=527 Participants
|
12 Participants
n=527 Participants
|
23 Participants
n=1054 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=527 Participants
|
1 Participants
n=527 Participants
|
1 Participants
n=1054 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=527 Participants
|
0 Participants
n=527 Participants
|
1 Participants
n=1054 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
1 Participants
n=527 Participants
|
0 Participants
n=527 Participants
|
1 Participants
n=1054 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
24 Participants
n=527 Participants
|
26 Participants
n=527 Participants
|
50 Participants
n=1054 Participants
|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
0 Participants
n=527 Participants
|
0 Participants
n=527 Participants
|
0 Participants
n=1054 Participants
|
|
Body Mass Index (BMI
|
31.6 kg/m^2
STANDARD_DEVIATION 6.5 • n=527 Participants
|
33.7 kg/m^2
STANDARD_DEVIATION 7.1 • n=527 Participants
|
32.6 kg/m^2
STANDARD_DEVIATION 6.8 • n=1054 Participants
|
|
Fitzpatrick Skin Type
Type I (Pale white skin; red or blond hair; blue/green eyes; freckles)
|
3 Participants
n=527 Participants
|
0 Participants
n=527 Participants
|
3 Participants
n=1054 Participants
|
|
Fitzpatrick Skin Type
Type II (Fair skin; red or blond hair; blue, hazel, or green eyes)
|
6 Participants
n=527 Participants
|
4 Participants
n=527 Participants
|
10 Participants
n=1054 Participants
|
|
Fitzpatrick Skin Type
Type III (Darker white; any eye or hair color)
|
3 Participants
n=527 Participants
|
7 Participants
n=527 Participants
|
10 Participants
n=1054 Participants
|
|
Fitzpatrick Skin Type
Type IV (Light brown skin)
|
2 Participants
n=527 Participants
|
2 Participants
n=527 Participants
|
4 Participants
n=1054 Participants
|
|
Fitzpatrick Skin Type
Type V (Brown skin)
|
7 Participants
n=527 Participants
|
10 Participants
n=527 Participants
|
17 Participants
n=1054 Participants
|
|
Fitzpatrick Skin Type
Type VI (Dark brown or black skin)
|
4 Participants
n=527 Participants
|
3 Participants
n=527 Participants
|
7 Participants
n=1054 Participants
|
PRIMARY outcome
Timeframe: During treatment, measured at the 8th minute of compressionsPopulation: Modified ITT population of subjects who completed ECP compressions with both devices, Pression Wave PRO and Predicate (active comparator)
The primary effectiveness endpoint was the average Diastolic Augmentation (DA) ratio for the 8th minute of compressions with each ECP device tested for each participant, as identified by the blinded Independent Waveform Evaluator. Diastolic Augmentation (DA) ratio, also referred to as Diastolic/Systolic (D/S) ratio and Effectiveness Ratio (ER), noninvasively characterizes the hemodynamic effect and thus the clinical effectiveness of ECP treatment. DA ratio is a unitless measure which is "calculated as the ratio of the peak diastolic amplitude divided by the peak systolic amplitude" \[Suresh et al., 1998\]. In a typical, non-augmented, cardiac cycle, the diastolic peak is seen as a small increase in the arterial waveform just after the aortic valve closes (dicrotic notch). With augmentation, the peak diastolic amplitude is distinctly elevated and may reach a significant proportion of the peak systolic amplitude or in some cases exceed it.
Outcome measures
| Measure |
Pression Wave PRO ECP System
n=95 Waveforms
10-minutes of ECP compressions applied by Pression Wave PRO ECP System, the experimental device
|
Predicate ECP Device
n=48 Participants
10-minutes of ECP compressions applied by the Predicate ECP Device, the active comparator
|
|---|---|---|
|
Diastolic Augmentation
|
0.83 Ratio
Interval 0.77 to 0.88
|
0.57 Ratio
Interval 0.52 to 0.62
|
SECONDARY outcome
Timeframe: At last compression after 10 minutes of compressionPopulation: Analyzed only for Pression Wave PRO ECP results. Due to the way that the predicate device records waveform data, Sponsor was unable to evaluate systolic unloading for the predicate ECP device.
The level of systolic unloading was recorded based on the systolic peaks during compressions compared to baseline PPG data. Systolic unloading is the percent change of peak systolic amplitude calculated as the difference of the compression waveform - non-compressed baseline waveform divided by amplitude at compression waveform. Systolic unloading components were measured using the peak systolic amplitude on the last compression waveform from the ECP session. The baseline non-compressed peak systolic amplitude was measured from the waveform immediately following the compressed waveform. Higher levels of systolic unloading are considered better. The predicate devices are documented to produce mean systolic unloading of approximately 11%.
Outcome measures
| Measure |
Pression Wave PRO ECP System
n=47 Participants
10-minutes of ECP compressions applied by Pression Wave PRO ECP System, the experimental device
|
Predicate ECP Device
10-minutes of ECP compressions applied by the Predicate ECP Device, the active comparator
|
|---|---|---|
|
Systolic Unloading (Mean)
|
9.2 Percent change of peak systolic pressure
Standard Deviation 22.8
|
—
|
SECONDARY outcome
Timeframe: At last compression after 10 minutes of compressionPopulation: Due to the way that the predicate device records waveform data, Sponsor was unable to evaluate systolic unloading for the predicate ECP device.
Systolic unloading is the ratio of the systolic peak during compressions divided by baseline systolic peak. Systolic unloading is represented by a percentage decrease of systolic peak value with and without compression. This value should be \< 1. The baseline systolic peaks after compressions will be used. Higher levels of systolic unloading are considered better. The predicate devices are documented to produce mean systolic unloading of approximately 11%.
Outcome measures
| Measure |
Pression Wave PRO ECP System
n=47 Participants
10-minutes of ECP compressions applied by Pression Wave PRO ECP System, the experimental device
|
Predicate ECP Device
10-minutes of ECP compressions applied by the Predicate ECP Device, the active comparator
|
|---|---|---|
|
Systolic Unloading (Categorical)
<11%
|
27 Participants
|
—
|
|
Systolic Unloading (Categorical)
>=11%
|
20 Participants
|
—
|
Adverse Events
Pression Wave PRO ECP System, Then Predicate ECP Device
Predicate ECP Device, Then Pression Wave PRO ECP System
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place